A Phase 2/3 interventional study of Empasiprubart IV in Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) and CIDP, sponsored by argenx. Withdrawn. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by argenx · Phase 2/3, Interventional, and Treatment
An alternative study design is under consideration.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of the study is to determine the correct dose of empasiprubart in adolescent participants. It also aims to evaluate if empasiprubart may work and how safe it is for the use in children living with CIDP.
The study consists of an open label treatment phase where participants will receive empasiprubart for up to 27 months approximately. After the final dose of empasiprubart, participants will enter a safety follow-up period for up to 14 months approximately.
The overall study duration for each participant is up to 43 months.
More information can be found here: clinicaltrials.argenx.com/emlight
137 studies on the registry are indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; 50 are open to participants now.
Browse Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies →argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive empasiprubart IV
Biological: Empasiprubart IV
Intravenous infusions of empasiprubart
Empasiprubart serum concentrations as input for a population PK-driven analysis to determine the effect of age and body size on CL and Vd
CL = Clearance; Vd = apparent volume of distribution.
Time frame: Up to 8 weeks
Free and total C2 levels as input for PK/PD modeling analysis
C2 = complement component 2.
Time frame: Up to 8 weeks
Incidence of AEs, SAEs and AESIs
AE = Adverse event ; SAE = Serious adverse event ; AESI = Adverse event of special interest.
Time frame: Up to 180 weeks
Empasiprubart serum concentrations over time
Time frame: Up to 180 weeks
Percentage reductions from baseline of free and total C2 levels over time
C2 = complement component 2.
Time frame: Up to 180 weeks
Incidence of ADA and NAb against empasiprubart in serum
ADA = antidrug antibody(ies); NAb = neutralizing antibody(ies).
Time frame: Up to 180 weeks
No study locations are listed for this record.
Plan to share: No
Start is estimated for Sep 2026; primary completion for Apr 2028, 19 months later.
How these figures are worked out, and which studies are left out of them.
An alternative study design is under consideration.
An alternative study design is under consideration.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Empasiprubart
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating →